Scinai Immunotherapeutics (SCNI) Current Assets (2017 - 2026)

Scinai Immunotherapeutics (SCNI) has 10 years of Current Assets data on file, last reported at $3.6 billion in Q1 2026.

• For the quarter ending Q1 2026, Current Assets changed N/A year-over-year to $3.6 billion; the trailing twelve-month figure through Mar 2026 stood at $3.6 billion (changed N/A YoY), and the FY2025 full-year result was $2.1 billion, up 85805.48% from the prior year.
• Current Assets improved to $3.6 billion in Q1 2026, from $2.1 billion in the prior quarter.
• In the past five years, Current Assets ranged from a high of $3.6 billion in Q1 2026 to a low of $1.5 million in Q2 2025.
• A 5-year average of $410.6 million and a median of $7.2 million in 2023 frame the typical range for Current Assets.
• Across the five-year window, Current Assets slumped 75.91% in 2024 and surged 85805.48% in 2025, its largest moves.
• Tracing SCNI's Current Assets over 5 years: stood at $14.4 million in 2022, then tumbled by 62.09% to $5.4 million in 2023, then tumbled by 56.1% to $2.4 million in 2024, then surged by 85805.48% to $2.1 billion in 2025, then surged by 75.95% to $3.6 billion in 2026.
• Business Quant data shows SCNI's Current Assets at $3.6 billion in Q1 2026, $2.1 billion in Q4 2025, and $1.5 million in Q2 2025.